Literature DB >> 10954526

Direct ex vivo kinetic and phenotypic analyses of CD8(+) T-cell responses induced by DNA immunization.

D E Hassett1, M K Slifka, J Zhang, J L Whitton.   

Abstract

CD8(+) T-cell responses can be induced by DNA immunization, but little is known about the kinetics of these responses in vivo in the absence of restimulation or how soon protective immunity is conferred by a DNA vaccine. It is also unclear if CD8(+) T cells primed by DNA vaccines express the vigorous effector functions characteristic of cells primed by natural infection or by immunization with a recombinant live virus vaccine. To address these issues, we have used the sensitive technique of intracellular cytokine staining to carry out direct ex vivo kinetic and phenotypic analyses of antigen-specific CD8(+) T cells present in the spleens of mice at various times after (i) a single intramuscular administration of a plasmid expressing the nucleoprotein (NP) gene from lymphocytic choriomeningitis virus (LCMV), (ii) infection by a recombinant vaccinia virus carrying the same protein (vvNP), or (iii) LCMV infection. In addition, we have evaluated the rapidity with which protective immunity against both lethal and sublethal LCMV infections is achieved following DNA vaccination. The CD8(+) T-cell response in DNA-vaccinated mice was slightly delayed compared to LCMV or vvNP vaccinees, peaking at 15 days postimmunization. Interestingly, the percentage of antigen-specific CD8(+) T cells present in the spleen at day 15 and later time points was similar to that observed following vvNP infection. T cells primed by DNA vaccination or by infection exhibited similar cytokine expression profiles and had similar avidities for an immunodominant cytotoxic T lymphocyte epitope peptide, implying that the responses induced by DNA vaccination differ quantitatively but not qualitatively from those induced by live virus infection. Surprisingly, protection from both lethal and sublethal LCMV infections was conferred within 1 week of DNA vaccination, well before the peak of the CD8(+) T-cell response.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10954526      PMCID: PMC116337          DOI: 10.1128/jvi.74.18.8286-8291.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  Rapid on/off cycling of cytokine production by virus-specific CD8+ T cells.

Authors:  M K Slifka; F Rodriguez; J L Whitton
Journal:  Nature       Date:  1999-09-02       Impact factor: 49.962

2.  Immune responses following neonatal DNA vaccination are long-lived, abundant, and qualitatively similar to those induced by conventional immunization.

Authors:  D E Hassett; J Zhang; M Slifka; J L Whitton
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

Review 3.  DNA immunization.

Authors:  D E Hassett; J L Whitton
Journal:  Trends Microbiol       Date:  1996-08       Impact factor: 17.079

4.  Efficiency and effectiveness of cloned virus-specific cytotoxic T lymphocytes in vivo.

Authors:  L S Klavinskis; A Tishon; M B Oldstone
Journal:  J Immunol       Date:  1989-09-15       Impact factor: 5.422

5.  Molecular analyses of a five-amino-acid cytotoxic T-lymphocyte (CTL) epitope: an immunodominant region which induces nonreciprocal CTL cross-reactivity.

Authors:  J L Whitton; A Tishon; H Lewicki; J Gebhard; T Cook; M Salvato; E Joly; M B Oldstone
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

6.  Plasmid DNA vaccines are effective in the absence of IFNgamma.

Authors:  D E Hassett; J Zhang; J L Whitton
Journal:  Virology       Date:  1999-10-10       Impact factor: 3.616

7.  Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice.

Authors:  D Kägi; B Ledermann; K Bürki; P Seiler; B Odermatt; K J Olsen; E R Podack; R M Zinkernagel; H Hengartner
Journal:  Nature       Date:  1994-05-05       Impact factor: 49.962

8.  DNA immunization confers protection against lethal lymphocytic choriomeningitis virus infection.

Authors:  M Yokoyama; J Zhang; J L Whitton
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

9.  Heterologous protection against influenza by injection of DNA encoding a viral protein.

Authors:  J B Ulmer; J J Donnelly; S E Parker; G H Rhodes; P L Felgner; V J Dwarki; S H Gromkowski; R R Deck; C M DeWitt; A Friedman
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

10.  Immune function in mice lacking the perforin gene.

Authors:  C M Walsh; M Matloubian; C C Liu; R Ueda; C G Kurahara; J L Christensen; M T Huang; J D Young; R Ahmed; W R Clark
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

View more
  22 in total

1.  Neonates mount robust and protective adult-like CD8(+)-T-cell responses to DNA vaccines.

Authors:  Jie Zhang; Nicole Silvestri; J Lindsay Whitton; Daniel E Hassett
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

2.  Detailed analysis of the CD8+ T-cell response following adenovirus vaccination.

Authors:  Teng Chih Yang; Kelley Dayball; Yong Hong Wan; Jonathan Bramson
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

3.  Immunization with non-replicating E. coli minicells delivering both protein antigen and DNA protects mice from lethal challenge with lymphocytic choriomeningitis virus.

Authors:  Matthew J Giacalone; Juan C Zapata; Neil L Berkley; Roger A Sabbadini; Yen-Lin Chu; Maria S Salvato; Kathleen L McGuire
Journal:  Vaccine       Date:  2006-12-26       Impact factor: 3.641

4.  Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines.

Authors:  Nia Tatsis; Julie C Fitzgerald; Arturo Reyes-Sandoval; Kimberly C Harris-McCoy; Scott E Hensley; Dongming Zhou; Shih-Wen Lin; Ang Bian; Zhi Quan Xiang; Amaya Iparraguirre; Cesar Lopez-Camacho; E John Wherry; Hildegund C J Ertl
Journal:  Blood       Date:  2007-05-17       Impact factor: 22.113

5.  T cell activation triggers reversible inosine-5'-monophosphate dehydrogenase assembly.

Authors:  Krisna C Duong-Ly; Yin-Ming Kuo; Matthew C Johnson; Joy M Cote; Justin M Kollman; Jonathan Soboloff; Glenn F Rall; Andrew J Andrews; Jeffrey R Peterson
Journal:  J Cell Sci       Date:  2018-09-05       Impact factor: 5.285

6.  Essential role for TLR9 in prime but not prime-boost plasmid DNA vaccination to activate dendritic cells and protect from lethal viral infection.

Authors:  Diane Rottembourg; Christophe M Filippi; Damien Bresson; Katrin Ehrhardt; Elizabeth A Estes; Janine E Oldham; Matthias G von Herrath
Journal:  J Immunol       Date:  2010-05-07       Impact factor: 5.422

7.  Using recombinant coxsackievirus B3 to evaluate the induction and protective efficacy of CD8+ T cells during picornavirus infection.

Authors:  M K Slifka; R Pagarigan; I Mena; R Feuer; J L Whitton
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

8.  A highly optimized DNA vaccine confers complete protective immunity against high-dose lethal lymphocytic choriomeningitis virus challenge.

Authors:  Devon J Shedlock; Kendra T Talbott; Christina Cress; Bernadette Ferraro; Steven Tuyishme; Karthik Mallilankaraman; Neil J Cisper; Matthew P Morrow; Stephan J Wu; Omkar U Kawalekar; Amir S Khan; Niranjan Y Sardesai; Karuppiah Muthumani; Hao Shen; David B Weiner
Journal:  Vaccine       Date:  2011-01-14       Impact factor: 3.641

9.  Two overlapping subdominant epitopes identified by DNA immunization induce protective CD8(+) T-cell populations with differing cytolytic activities.

Authors:  F Rodriguez; M K Slifka; S Harkins; J L Whitton
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

10.  Chimeric Hemagglutinin-Based Influenza Virus Vaccines Induce Protective Stalk-Specific Humoral Immunity and Cellular Responses in Mice.

Authors:  Angela Choi; Badiaa Bouzya; Klaus-Daniel Cortés Franco; Daniel Stadlbauer; Arvind Rajabhathor; Ronan N Rouxel; Roland Mainil; Marie Van der Wielen; Peter Palese; Adolfo García-Sastre; Bruce L Innis; Florian Krammer; Michael Schotsaert; Corey P Mallett; Raffael Nachbagauer
Journal:  Immunohorizons       Date:  2019-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.